These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biodistribution and first clinical results of Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994 [TBL] [Abstract][Full Text] [Related]
3. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Velikyan I; Xu H; Nair M; Hall H Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of [ Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872 [TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461 [TBL] [Abstract][Full Text] [Related]
8. Altered biodistribution of [ van de Weijer T; Bemer F; de Vos-Geelen J; Hermans B; Mitea C; van der Pol JAJ; Lodewick T; Wildberger JE; Mottaghy FM Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of [ Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796 [TBL] [Abstract][Full Text] [Related]
10. Clinical impact of using [ Leupe H; Pauwels E; Vandamme T; Van den Broeck B; Lybaert W; Dekervel J; Van Herpe F; Jaekers J; Cleeren F; Hofland J; Brouwers A; Koole M; Bormans G; Van Cutsem E; Geboes K; Laenen A; Verslype C; Stroobants S; Deroose CM J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519 [TBL] [Abstract][Full Text] [Related]
12. Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966 [TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033 [TBL] [Abstract][Full Text] [Related]
14. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [ Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145 [TBL] [Abstract][Full Text] [Related]
17. The Search for an Alternative to [ Waldmann CM; Stuparu AD; van Dam RM; Slavik R Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834 [TBL] [Abstract][Full Text] [Related]
18. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265 [TBL] [Abstract][Full Text] [Related]
19. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [ Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496 [TBL] [Abstract][Full Text] [Related]
20. [Value of Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]